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Normal cell growth is governed by a complicated biological system, featuring multiple levels of
control, often deregulated in cancers. The role of microRNAs (miRNAs) in the control of gene
expression is now increasingly appreciated, yet their involvement in controlling cell proliferation is
still not well understood. Here we investigated the mammalian cell proliferation control network
consisting of transcriptional regulators, E2F and p53, their targets and a family of 15 miRNAs.
Indicative of theirsigniﬁcance, expression of these miRNAs is downregulated in senescent cells and
in breast cancers harboring wild-type p53. These miRNAs arerepressed byp53 in an E2F1-mediated
manner. Furthermore, we show that these miRNAs silence antiproliferative genes, which
themselves are E2F1 targets. Thus, miRNAs and transcriptional regulators appear to cooperate in
the framework of a multi-gene transcriptional and post-transcriptional feed-forward loop. Finally,
we show that, similarly to p53 inactivation, overexpression of representative miRNAs promotes
proliferation and delays senescence, manifesting the detrimental phenotypic consequence of
perturbations in this circuit. Takentogether, these ﬁndings position miRNAs as novel key players in
the mammalian cellular proliferation network.
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Introduction
The tumor suppressor p53 is considered a central regulator of
cell-fate decisions. Activation of p53 can induce several
cellular responses, including cell-cycle arrest, senescence
and apoptosis. Thus, absence of functional p53 predisposes
cells to neoplastic transformation. Accordingly, mutations of
this gene are highly common in human cancers (Hussain and
Harris, 1999). p53 is a sequence-speciﬁc transcription factor
(TF) that exerts many of its downstream effects by activating
gene transcription (Ryan et al, 2001). Nevertheless, additional
transactivation-independent functions of p53 contribute to its
tumor suppressive activity, including protein–protein interac-
tions with additional TFs and other cell-fate regulators. The
importance of transcriptional regulation by p53 is exempliﬁed
by the fact that most p53 tumor-derived mutants are defective
in DNA binding and incapable of transactivation (Kern et al,
1991).Inadditiontoitscapabilitytoinducegenetranscription,
p53 activation results in extensive gene repression (Ginsberg
et al, 1991). Direct and indirect transcriptional repression by
p53 is considered important for its tumor suppressive
functions, such as induction of cell-cycle arrest and apoptosis
(Ho and Benchimol, 2003).
microRNAs (miRNAs or miRs in short) are a recently
discoveredclassofsmallnon-codingRNAspeciesthatregulate
gene expression at the post-transcriptional level. Approxi-
mately half of the known miRs are encoded in regions of the
genome that aredistal to known genes,whereas the remaining
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www.molecularsystemsbiology.comreside in introns, or in rare cases in exons, of coding genes,
usually in the same orientation as the mRNA. Additionally,
some miRs are clustered in the genome and are transcribed as
polycistrons that may contain up to B50 mature miRs (Bartel,
2004). With the recent identiﬁcation of miRs that regulate
cancer-related processes such as apoptosis, proliferation and
differentiation, these RNA species emerge as important
regulators of cancer initiation and progression. Accordingly,
mutation and transcriptional deregulation of miRs have been
linked to cancer (Esquela-Kerscher and Slack, 2006). Deregu-
lated miRs were suggested to exert their function in cancer
through silencing of key cell-fate regulators, as shown for let-7
and Ras (Johnson et al, 2005), as well as for miR-106b and p21
(Ivanovska et al, 2008; Petrocca et al, 2008).
In a previous work we suggested that miRs cooperate with
certain TFs in the regulation of mutual sets of target genes,
allowing the coordinated modulation of gene expression both
transcriptionallyandpost-transcriptionally.Speciﬁcally,wefound
a recurring network motif in which a TF regulates the miR with
whichitcooperatesinregulatingacommonsetoftargets,creating
a feed-forward loop (FFL). One such case involved E2F and the
miR-106b/93/25 polycistron (Shalgi et al, 2007).
Several studies have implicated p53 in the regulation of miR
expression (Xi et al, 2006; Chang et al, 2007; He et al, 2007;
Raver-Shapira et al, 2007; Tarasov et al, 2007; Kumamoto et al,
2008). These studies exploited various high-throughput
methods to identify p53-regulated miRs in several cellular
systems with differential p53 status. Although the resulting
candidatelistsfromeachstudydifferedconsiderably,probably
due to differences in the cellular contexts and p53 activation
signals, all studies identiﬁed members of the miR-34 family as
direct transactivation targets of p53. In line with p53 function,
induction ofmiR-34familymemberswassuggestedtomediate
cell-cycle arrest, apoptosis and senescence. Importantly, none
of these studies focused on miRs,whose expressionnegatively
correlated with p53 activation, and which are likely repressed
by this tumor suppressor.
Here, we report the identiﬁcation of a large set of miRs, the
expression of which constitutes a recurring signature in
several experiments. The members of this signature are
transcriptionally repressed by p53 in primary cells and in
human breast cancers. This signature is comprised of known
cancer-associated miRs as well as newly proposed ones, and
includes the miR-106b/93/25 polycistron. We implicate E2F1
in the p53-dependent repression of these miRs, and demon-
strate the oncogenic potential of the miR-106b/93/25 poly-
cistron. Finally, we delineate a network architecture that
includes the transcription factor E2F1 and a family of miRs,
which co-regulate mutual target genes transcriptionally and
post-transcriptionally, thereby enhancing cellular prolifera-
tion. This FFL is repressed by p53, possibly to promote
senescence and suppress cancer progression.
Results
Identiﬁcation of p53-regulated miRNAs in primary
human cells and in human breast cancers
To identify novel p53-regulated miRs, we established two
isogenic cell cultures that differ in their p53 status and
analyzed their miRNA proﬁles both under normal conditions
and in contexts involving p53 activation. WI-38 primary
humanﬁbroblasts wereinfected with a retrovirus encoding for
the p53-inactivating peptide, GSE56 (Ossovskaya et al, 1996).
These cells (GSE) and their active p53 counterparts (con) were
treated with the DNA-damaging agent doxorubicin or grown
until the onset of replicative senescence (the establishment of
the system is depicted in Supplementary Figure S1). Analysis
of miRNA expression patterns revealed several expression
clusters (see Materials and methods). Notable among these
was a cluster populated with miRs, the expression of which
was negatively regulated byp53 under normal conditions. The
cluster showed additional downregulation in senescent cells,
which was attenuated upon p53 inactivation. We named this
cluster the ‘p53-repressed miR cluster’ (Figure 1A). Notably,
doxorubicin treatment, which resulted in a considerable
activation of p53 and its mRNA targets (Supplementary Figure
S1), did not signiﬁcantly affect the levels of these miRs.
Interestingly, a signiﬁcant number of miRs from this cluster
were also clustered together in a similar experiment, in which
miR expression was proﬁled in young and senescent human
embryonicﬁbroblasts(WI-38andMRC5).Thisclusteristermed
‘senescence-repressed miR cluster’ (Figure 1B). The signiﬁcant
overlapbetweentheclusters(P-value¼3.2 10
 4)isinteresting
as the second experiment was not designed to discover p53-
regulated miRs, but rather to identify a general signature of
miRsthatarealtereduponreplicativesenescence.However,p53
activity was increased in both senescent ﬁbroblast cultures
(data not shown). Strikingly, clustering analysis of miR
expression data derived from a set of breast cancer tumors
with differing p53 status also resulted in a cluster highly
overlapping the ‘p53-repressed miR cluster’ (Figure 1C;
P-value¼1.11 10
 5) (samples, p53 status and histological
grading were described by Naume et al (2007) and Sorlie et al
(2006), and detailed description of the mutation status is listed
in Supplementary Table S1). The ‘breast cancer p53-repressed
miR cluster’ was comprised of miRs, the expression of which
was negatively correlated with the presence of a wild-type p53
in the tumors. Additionally, the miRNA expression and p53
statuspartiallycorrelatedwithtumorgrade,asalmostallcancer
samples that contained a mutant p53 and expressed high levels
of the miRs were derived from high-grade tumors.
We thus revealed a recurring signature of miRs that are
coordinately regulated both in primary human cells in vitro
and in human breast tumors in vivo. We suggest that these
miRs are repressed by wild-type p53 during both normal
growth and cancer progression.
The presented clusters contain families
of paralogous cancer-related miRNAs
Interestingly, 15 miRs represented in the three clusters
(Figure 1) are transcribed from three homologous genomic
loci, reported earlier to be paralogs that evolved from a
commonevolutionaryorigin(TanzerandStadler,2004).These
include miRs-106b/93/25, which residewithin an intronof the
cell-cycle gene ‘minichromosome maintenance protein
7’ (MCM7); miRs-17/18a/19a/20a/19b-1/92a-1 (miR-17-92
polycistron), which are transcribed as the non-coding RNA
c13orf25, and miRs-106a/18b/20b/19b-2/92-2 (miR-106a-92
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indicate that not only were these miRNA sequences and
genomic organization conserved during evolution but also
was their transcriptional regulation. Additional well-repre-
sented miRs in theclustersinclude the miR-15b/16 polycistron
and miR-155.
Figure 1 miRNA clusters derived from three different datasets. The ﬁgure depicts three different expression matrices for miRNA clusters that originated from three
microarray experiments. miRs appearing in all three clusters are indicated in red bold font. miRs appearing in two clusters are indicated in black bold font. (A) The ‘p53-
repressed miR cluster.’ Primary WI-38 cells that were infected with the p53-inactivating peptide GSE56 (GSE) and their empty vector control counterparts (Con) were
analyzed for miRNA expression at early passage (Young), after doxorubicin treatment (0.2mg/ml, 24h) of early passage cells (Dox), and at the onset of replicative
senescence (Old). A cluster of miRs that were repressed by p53 at normal conditions and in senescent cells is presented. (B) The ‘Senescence-repressed miR cluster.’
Primary WI-38 and MRC5 cells were analyzed for miRNA expression at early passage (Young) and at the onset of replicative senescence (Old). A cluster of miRs that
were repressed upon senescence inboth cell types is presented. (C)The ‘breast cancer p53-repressed miRcluster.’ Human primary breast cancers described bySorlie
etal(2006)andNaumeetal(2007)wereanalyzedfortheirmiRNAproﬁles.AclusterofmiRs,theexpressionofwhichwasanticorrelatedwiththepresenceofawild-type
p53 in the tumor is presented. p53 status was determined using TTGE and sequencing of exons 2–11. Grading was performed using histopathological evaluation
according to the modiﬁed Scarff–Bloom–Richardson method and is represented by blue for grade 1, green for grade 2 andred for grade 3. (D)Venn diagrams depicting
theoverlapsbetweenclusterpairs.ThevaluesineachcirclerepresentthenumberofmiRsfromtheindicatedclusterthatwasdetectedbythearraycorrespondingtothe
secondcluster.ThevaluesinthecircleoverlappingregionsrepresentthenumberofmiRsthataresharedbetweenthetwoclusters.HypergeometricP-valuesonthesize
of the overlaps are provided.
p53-repressed miRNAs promote proliferation
R Brosh et al
& 2008 EMBO and Macmillan Publishers Limited Molecular Systems Biology 2008 3Many members of the clusters are overexpressed in various
tumors, consistent with the frequent p53 loss of function in
cancer, and some were shown to possess oncogenic functions.
For example, miR-92, miR-106a, miR-17-5p, miR-20a and miR-
155, which appear in at least two expression clusters, were
reported to be overexpressed in solid tumors (Volinia et al,
2006). Members of the miR-17-92 polycistron are over-
expressed in lymphomas and in lung and colorectal carcino-
mas (He et al, 2005; Schetter et al, 2008), and were shown to
accelerate tumor growth (O’Donnell et al, 2005). Interestingly,
the MCM7 gene that contains three of the clusters’ miRs in its
intron (miRs-106b/93/25) is ampliﬁed or overexpressed in
diverse types of cancers (Ren et al, 2006), as are its resident
miRs (Petrocca et al, 2008).
Representative miRNAs show p53-dependent
repression during senescence in many cell types
To further validate our data, we generated two additional
humanisogeniccellculturepairsfromtheIMR90lungprimary
ﬁbroblasts and from prostate-cancer-associated ﬁbroblasts.
Each culture was infected with a retrovirus encoding for either
a small hairpin RNA (shRNA) targeting p53 (p53i) or a control
shRNA (con), and grown until the onset of replicative
senescence. p53 knockdown, which signiﬁcantly reduced the
mRNA and protein levels of both p53 and its target p21,
delayed the onset of senescence by approximately 10 popula-
tiondoublings(PDLs) (Figure2A; SupplementaryFigureS2C).
Forthesecelltypes,aswellasfortheWI-38cells,wecompared
the levels of representative miRs that appear in the three
expression clusters using TaqMan miRNA assays. Analyses of
miR-106b and miR-17-5p, as well as their host transcripts
MCM7 and c13orf25, respectively, revealed transcriptional
repression upon replicative senescence in all three tested cell
cultures in a manner that was partially or completely p53
dependent (Figure 2B). Additionally, the non-coding RNA BIC
and its resident miR-155 were also transcriptionally repressed
in a p53-dependent manner upon replicative senescence
(Supplementary Figure S2D).
Co-clustering of miRNA and mRNA expression
data from human breast cancers reveals two
distinct groups of p53-repressed miRNAs
To gain further insights into the regulation and function of the
identiﬁed miRNA signature, we exploited previously pub-
lished mRNA proﬁling (Sorlie et al, 2006; Naume et al, 2007),
performed on the same set of breast cancer specimens from
which the ‘breast cancer p53-repressed miR cluster’w a s
derived. The mRNA and miRNA array data were combined
into one set of expression proﬁles, and were clustered into 40
co-clusters; each may consist of both miRs and mRNAs
(Figure 3). Interestingly, the members of the ‘breast cancer
p53-repessed miR cluster’ were separated into two distinct
Figure 2 Validation of microarray data. Inactivation ofp53 bythe GSE56 peptide (GSE) or shRNA(p53i) inthree different humanprimary ﬁbroblasts delays replicative
senescence and attenuates the repression ofmiRs andtheir hosts upon senescence. (A)Growth curves for the humanprimary ﬁbroblasts WI-38 and IMR90 andfor the
prostate cancer-associated ﬁbroblasts (CAFs) PF179. PDLs, population doublings. (B) QRT–PCR for miR-106b and miR-17-5p, and their host transcripts MCM7 and
c13orf25, respectively, in early passage (Young) versus late passage (Old) ﬁbroblasts. Data are represented as mean±s.d.
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functional annotation using DAVID (Dennis et al, 2003) and
by promoter motif analyses using AMADEUS (Linhart et al,
2008) of the mRNAs from each co-cluster. Of 37 miRs, 31 were
co-clustered (Figure 3A, red cluster; Supplementary Table S2)
with genes highly enriched for cell-cycle-related anno-
tations (Figure 3D; enrichment P-value for ‘cell-cycle’
annotation¼8.5 10
 20, see Supplementary Table S3A for
other enriched annotations) and for regulatory binding motifs
of known cell-cycle-related TFs such as E2F (Figure 3F;
P-value¼2.5 10
 16). All members of the three paralogous
polycistrons described above were included in this ‘cell-cycle-
associated co-cluster,’ as were their hosts MCM7 and c13orf25.
Supporting the notion that this cluster consists mainly of
Figure 3 Co-clustering of miRNA and mRNA expression data from human breast cancers. (A) A dendrogram for the expression data based on hierarchical clustering
and average linkage. Data were clustered into 40 clusters, which are indicated by different colors of the dendrogram. miRs from the ‘breast cancer p53-repressed miR
cluster’ were mapped to the red (cell cycle) and purple (immune response) clusters. (B) Expression matrix of the mRNAs and miRNAs analyzed. For p53 status and
tumor grade analyses, see Figure 1 legend. Breast cancer samples are indicated by numbers below the matrix. (C) The bar indicates the position of miRs along the
expressionmatrix.(D, E)Functional annotationanalysisfor ‘cellcycle’(C)and‘immuneresponse’(Imm. Res.)(D)terms.Theplotsrepresent thedensity (from0to1)of
mRNAs corresponding to each annotation term in windows of 100 genes. (F, G) Density plots for the appearance of the E2F and ISRE motifs, the most enriched
elements in the cell cycle and immune response co-clusters, respectively. Red lines indicate the background levels of each motif, calculated as the fraction of genes in
the genome containing the motif. (H) Density plot for cell-cycle periodic genes as deﬁned by Whitﬁeld et al (2002).
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previously published list of genes expressed in a cell-cycle
periodic manner (Whitﬁeld et al, 2002), and found a
signiﬁcant enrichment of periodically expressed genes in this
cluster (Figure 3H; P-value¼4.9 10
 17). Another co-cluster,
which contained six miRs (Figure 3A, purple cluster;
Supplementary Table S2), was comprised of genes highly
enriched for immune response-related functions (Figure 3E;
P-value for ‘immune response’ annotation¼1.2 10
 48, see
Supplementary TableS3B forotherenriched annotations). The
promoters of these genes were enriched for immune response-
related motifs such as interferon-stimulated-responsive ele-
ment (Figure 3G; P-value¼1.62 10
 12) as well as for the IRF
and NF-kB motifs (data not shown). Importantly, both mRNAs
andmiRNAsofbothco-clustersweredownregulatedintumors
that harbor wild-type p53, suggesting that our miR signature
belongs to a larger transcriptional program that mediates p53-
dependent gene repression of both RNA types.
The miRNAs from the ‘cell-cycle-associated
co-cluster’ are associated with p53 and E2F
in a proliferation-related regulatory network
We have reported earlier the identiﬁcation and characteriza-
tion of an mRNA cluster termed the ‘proliferation cluster’ that
consists mainly of cell-cycle-related genes (Milyavsky et al,
2005). Thisclusteremerged frommRNA proﬁling of an invitro
transformation process, in which primary WI-38 cells were
gradually transformed into tumorigenic cells. Importantly, the
‘proliferation cluster’ is one of the most prominent expression
signatures revealed when tumors are compared to normal
tissues or when highly proliferating cells are comparedto slow
growing cells, and contains many cell-cycle periodic genes
(Whitﬁeld et al, 2006). The expression pattern of the
‘proliferation cluster’ is highly similar to that of the
‘p53-repressed miR cluster’; i.e. the ‘proliferation cluster’
mRNAs display p53-dependent downregulation. The similar-
ity in expression patterns prompted us to hypothesize that
both clusters share a common transcriptional program. It was
shown earlier that the p53-mediated repression of the
‘proliferation cluster’ was mediated through E2F (Tabach
et al, 2005). Providing further support, the promoters of the
mRNAs from the ‘cell-cycle-associated co-cluster’ are highly
enriched with E2F-binding motifs (Figure 3F), and in
particular, a conserved E2F-binding site is found upstream of
the three miRNA polycistrons (Supplementary Figure S3A and
Supplementary Table S4). Conﬁrming these predictions,
chromatin immunoprecipitation analysis revealed that E2F1
binds to its conserved motifs upstream of each of the three
polycistrons(Figure4A).Similarly,itwasshownrecentlythatthe
miR-17-92 and the miR-106b/93/25 polycistrons are transcrip-
tionally activated by E2F family members (O’Donnell et al, 2005;
Sylvestre et al, 2007; Woods et al, 2007; Petrocca et al, 2008).
In view of the above, it appears conceivable that the miRs
from the ‘cell-cycle-associated co-cluster’ are transcriptionally
activated by E2F, and that p53 exerts its repression through
E2F inhibition. In agreement with the observed downregula-
tion of the ‘p53-repressed miR cluster’ in senescence, it was
shown that E2F activity is signiﬁcantly downregulated in
senescent cells (Campisi and d’Adda di Fagagna, 2007). In
addition, the miRs presented here are proposed to be novel
members of the well-established ‘proliferation cluster.’
The p53-dependent repression of miRNAs
from the ‘cell-cycle-associated co-cluster’
is mediated through E2F1
To experimentally test whether the cell-cycle-associated miRs
and their host mRNAs are transcriptionally activated by E2F1,
we infected primary WI-38 cells with E1A, a viral oncoprotein
that disrupts pRb-E2F complexes and leads to an upregulation
of the endogenous E2F activity (Fattaey et al, 1993). As
expected, stable overexpression of E1A resulted in elevated
levels of candidate miRNAs and host mRNAs, which were part
of the ‘cell-cycle-associated co-cluster,’ that together represent
all three paralogous polycistrons (Figure 4B). Speciﬁcally, the
MCM7 gene and its resident miRNAs miRs-106b/93/25; the
non-codingRNAc13orf25andits residentmiR-17-5p; andmiR-
106a, which represents the miR-106a-92 polycistron, were all
upregulated following E2Factivation. We note that the level of
miR-155, which belongs to the ‘immune response co-cluster’,
was not upregulated by E2F (Supplementary Figure S3E).
To investigate the kinetics of the miRNA’s transcriptional
activation by E2F1, we infected WI-38 cells with a retrovirus
encoding for an E2F1 protein fused to a modiﬁed estrogen
receptor (ER) ligand-binding domain. Treatment of ER-E2F1-
expressing cells with 4-hydroxytamoxifen (4-OHT) permits
ER-E2F1 translocation to the nucleus, thereby inducing its
transactivation activity. As depicted in Figure 4C, as early as
4hafterER-E2F1 activation by 4-OHT, signiﬁcant upregulation
of the candidate miRNAs and host transcripts was already
evident. The miRNAs and their hosts peaked after 8–10h of
4-OHT treatment, similarly to Cyclin E, a known E2F1 target. It
is noted that upregulation of MCM7 and its resident miRNAs
following 4-OHT treatment was also observed in ER-E2F1
expressing lung carcinoma cells (H1299) and osteosarcoma
cells (U2OS) (Supplementary Figure S3B and C). Finally, to
strengthen the notion that E2F1 directly transactivates the
miRNAs, we treated ER-E2F1 expressing WI-38 cells with
4-OHT in the presence or absence of cycloheximide, which
inhibits protein biosynthesis and should attenuate the induc-
tion of the miRNAs if translation of a secondary mediator is
required. As depicted in Supplementary Figure S3D, the
induction of the miRNAs was not inhibited by cycloheximide.
Altogether,theseresultsindicatethatE2F1candirectlybindits
cognate sites upstream of the polycistronic miRNAs and
activate their transcription.
Having shown that representative miRs are activated by
E2F1inoursystem,wesettotest whethertheir p53-dependent
repressionismediatedthroughmodulationofE2F1activity.To
thatend,weinfectedWI-38cellswitharetrovirusencodingfor
either an shRNA targeting p53 (p53i) or a control shRNA (con)
and treated them with Nutlin-3, a small molecule that
stabilizes the p53 protein by inhibiting its Mdm2-dependent
ubiquitylation and degradation (Vassilev et al, 2004), thereby
inducing p53 activation in a non-genotoxic manner. Nutlin
treatment resulted in a robust p53 protein accumulation,
accompanied by p21 mRNA and protein induction (Figure 5A
p53-repressed miRNAs promote proliferation
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Remarkably, E2F1 mRNA and protein levels were down-
regulated upon Nutlin treatment in a p53-dependent manner.
Cyclin E showed a similar pattern, supporting the notion that
E2F1 downregulation was accompanied by a reduction in E2F
activity. Accordingly, both MCM7 and its resident miR-106b
were signiﬁcantly downregulated in a p53-dependent manner
(Figure 5A) along with other miRs from the ‘cell-cycle-
associated co-cluster’ (data not shown). Thus, treatment with
Nutlin, a non-genotoxic p53 activator, resulted in a p53-
dependent transcriptional repression of mRNAs and miRNAs
with associated cell-cycle functions. To substantiate the causal
relationship between the p53-dependent reduction of E2F1
activity and the repression of the miRs and their hosts, we
treated control and E1A-expressing WI-38 cells with Nutlin.
As depicted in Figure 5C and D, E1A induced the expression
and prevented the Nutlin-dependent repression of E2F1
as well as of its target Cyclin E. Most signiﬁcantly, E1A
abolished the downregulation of MCM7 and miR-106b upon
Nutlintreatment.AsimilarpatternwasobservedformiR-17-5p
and its host c13orf25 (data not shown). Finally, we stably
knocked down E2F1 using retroviral-encoded shRNA in WI-38
cells in combination with Nutlin treatment, and measured the
levels of miRs-106b/25/93 (Figure 5E), as well as the protein
levels of p53, p21 and E2F1 (Figure 5F). Indeed, the knock
down of E2F1 resulted in reduced levels of the miRNAs.
Supporting the notion that repression of the miR-106b/93/25
polycistron by p53 is mediated through E2F1 inhibition, Nutlin
treatment of the E2F1-knockdown cells had very little effect as
compared with the control cells.
We therefore conclude that E2F1 inhibition by p53 is
necessary for the downregulation of MCM7 and its resident
miRNAs. The same mechanism may underlie the p53-
dependent downregulation of additional miRs from the
Figure 4 E2F binds the promoters of the paralogous miRNA polycistrons and induces their transcription. (A) E2F1 binds conserved E2F sites upstream of eachof the
paralogous miRNA polycistrons. ChIP analysis was performed on U2OS cells with an anti-E2F1 antibody (IP: E2F1) and a control antibody against HA (IP: HA).
The precipitated DNA was measured using QRT–PCR. The b-actin gene serves as a negative control for E2F1 binding. Values were normalized to the levels of
b-tubulin. For schematic representation of the polycistrons’ genomic organization and corresponding E2F sites, see Supplementary Figure S3A. (B) E2F activation by
E1A induces the polycistronic miRNAs. WI-38 cells were infected with the oncoprotein E1A or a control vector (Con) and selected with puromycin. QRT–PCR revealed
upregulation of the known E2F1 target, Cyclin E, as well as of host transcripts and miRNAs, representatives of the three paralogous polycistrons (miRs-106b/93/25,
miR-17-92 andmiR-106a-92).(C)E2F1 activation results in rapid induction of the polycistronic miRNAs. WI-38 cells were stably infected with ER-E2F1 andtreated with
4-OHT (300nM) for the indicated time periods. QRT–PCR analysis was performed to measure the levels of miRNAs and mRNAs. QRT–PCR data are represented as
mean±s.d.
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& 2008 EMBO and Macmillan Publishers Limited Molecular Systems Biology 2008 7Figure 5 MCM7 and miR-106b are repressed by Nutlin-activated p53 inan E2F-dependent manner. (A, B) WI-38 were infected with a retrovirus encoding for either a
small hairpin RNA targeting p53 (p53i) or a control shRNA (Con) and treated with 10mM Nutlin-3 for 24 or 48h. QRT–PCR (A) and western blotting (B) analyses
demonstrated p53 stabilization by Nutlin, which resulted in activation of p21 and repression of E2F1 mRNA and protein levels. MCM7 and its resident miR-106b were
repressed in a p53-dependent manner upon Nutin-3 treatment. (C, D) WI-38 cells were infected with E1A or an empty vector control (Con) and treated with 10mM
Nutlin-3for24h.E1AelevatedE2Ftransactivationactivity,resultingintheinductionofCyclinEandE2F1itselfaswellasofMCM7andmiR-106b.Nutlintreatmentofthe
control cells repressed transcription of E2F1 and its targets. E1A abolished this repression, indicating that the repression of E2F1 by p53 is necessary for the
p53-dependent downregulation of MCM7 and miR-106b. In (A, C), statistically signiﬁcant difference in expression (t-test; P-valueo0.01) between the non-treated
samplesandtheNutlin-treated samples(atboth24 and48h)ismarkedbyasterisks. (E,F)WI-38 cellswereinfected witharetrovirusencoding foreitherasmallhairpin
RNAtargetingE2F1(E2F1i)oracontrolshRNA(Con)andtreatedwith10mMNutlin-3for48h.QRT–PCR(E)andwesternblot(F)analysesdemonstratedrepressionof
E2F1anditstargetsmiRs-106b/93/25,aswellasactivationofp53andp21uponNutlintreatment.E2F1knockdownmimickedtheeffectofNutlintreatmentinrepressing
the miR-106b/93/25 polycistron. Nutlin treatment in the presence of E2F1 shRNA had little effect on the miRs, indicating that E2F1 inhibition mediates the repression of
the miRs by Nutlin-activated p53. GAPDH protein levels serve as loading controls in (B, D, F). QRT–PCR data are represented as mean±s.d.
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logous polycistrons.
Cell-cycle-associated miRNAs target key cell-cycle
regulators and affect pivotal characteristics of
proliferation
Next, we set out to identify the functions of the p53-repressed
miRs. We focused on the miR-106b/93/25 polycistron as a
representative member of the large family of miRs that
includes also the miR-17-92 and miR-106a-92 polycistrons.
We overexpressed the genomic region encoding miRs-106b/
93/25, which corresponds to an intron of the MCM7 gene in
young WI-38 cells and in MCF10A mammary epithelial cells,
both characterized by low basal expression of these miRs.
Following our previous computational prediction of E2F and
miR-106b/93/25 involvement in a FFL, in which they both
target a mutual set of genes (Shalgi et al, 2007), we compiled a
listoftheirmutualpredictedtargets(SupplementaryTableS5).
Interestingly, many of these predicted targets participate in
cell-cycle regulation (P-value for ‘cell-cycle’ annotation
enrichment¼1.4 10
 10). Another key cell-cycle regulator,
p21, was recently reported as a target for miR-106b (Ivanovska
et al, 2008), and is a known target of both E2F1 (Gartel et al,
1998)andp53.Wethenmeasuredtheproteinlevelsofselected
predicted targets in the miR-106b/93/25-overexpressing cells
(Figure 6). We observed downregulation of p21, as well as of
pRBandp130,whichweresuggestedearlier,basedonreporter
assays, as potential targets of miR-106a and the miR-17-92
Figure 6 Overexpression of miR-106b/93/25 polycistron results in silencing of cell-cycle-related genes. WI-38 primary ﬁbroblasts and MCF10A mammary cells were
infected with a retrovirus encoding for either the genomic region that contains miRs-106b/93/25 or an empty vector control. (A) Western blot analysis of cell-cycle-
regulatingtargetsoftheoverexpressedmiRs.OverexpressionofmiRs-106b/93/25reducedtheproteinlevelsofE2F1,pRb,p130,E2F1andp21inbothcelltypesandof
p57 in WI-38 cells. b-Tubulin levels serve as a loading control. The scanned blots were analyzed using the ImageJ software. Values represent the fold change of each
protein relative to the empty vector-infected cells, and were normalized to the levels of b-tubulin. (B) QRT–PCR analysis of the mRNA levels of the genes presented in
(A).ValuesrepresentthefoldchangeofeachmRNArelativetotheemptyvector-infectedcells.Dataarerepresentedasmean±s.d.(C)Expressionpatternofpredicted
targets of at least ﬁve miRs from the ‘p53-repressed miR cluster.’ mRNA expression levels were derived from WI-38 cells that underwent immortalization and gradual
in vitro transformation (the cell status is indicated below) as described by Milyavsky et al (2003). This expression pattern was found to be signiﬁcantly coherent (EC
score¼0.14, EC P-value¼5 10
 3). See Supplementary dataset S4 for the expression values. (D) Promoter analysis performed on the genes from (C) (using
AMADEUS) revealed enrichment for E2F motif (P-value¼2.2 10
 13). Genes with E2F motif in their promoter are indicated in black in the bar on the right (and in
Supplementary dataset S4).
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Interestingly, E2F1, which was shown to be a target of miR-17-
5p and miR-20a (O’Donnell et al, 2005), and is predicted by
PicTar (Krek et al, 2005) to be a target for both miR-106b and
miR-93, was signiﬁcantly downregulated as well. We also
observed downregulation of p57 in WI-38 cells, in agreement
with PicTar predictions (Figure 6A; Supplementary Figure S4).
Notably, these proteins have deﬁned functions in the regula-
tion of the cell cycle, most of them being negative regulators of
proliferation. As the mRNA levels of p57, p21, pRb and p130
didnotdecreaseinWI-38cellsandonlymarginallyinMCF10A
cells (Figure 6B), the reduction in their protein levels most
likely stems from translational inhibition and not mRNA
degradation. Considering the above, it is unlikely that the
reduction in the targets’protein levels stems from reduced E2F
transcriptional activity. In contrast, E2F1 mRNA levels were
reduced in both cell lines that express the miR-106b/93/25
polycistron, in agreement with Petrocca et al (2008).
To gain independent support for the role of the ‘p53-
repressed miR cluster,’ we investigated the expression pattern
of genes that are targeted by these miRs in the above-
mentioned transformation system, where primary WI-38 cells
were gradually transformed into tumorigenic cells (Milyavsky
et al, 2005). Interestingly, targets harboring predicted sites for
multiple miRs from the ‘p53-repressedmiR cluster’ within their
30-UTR had signiﬁcantly coherent expression patterns (Pilpel
etal,2001)duringthetransformationprocess(Figure6C).This
observation means that genes that are targeted by multiple
miRs from the ‘p53-repressed miR cluster’ are signiﬁcantly co-
expressedduringthetransformationprocessascomparedwith
random sets of genes. Furthermore, not only are these targets
expressed similarly to one another but also the actual
expression pattern of many of them is consistent with the
pro-proliferative role of the miRs that regulate them, i.e. the
expression of the majority of the genes in this target set was
decreased when cells gained the accelerated proliferation
phenotype (designated as ‘fast growing’). Furthermore,
promoter analysis, using the AMADEUS algorithm (Linhart
et al, 2008), of these predicted target genes, revealed the E2F-
binding site as one of the most highly enriched motifs
(P-value¼2.2 10
 13). This supports our general notion that
E2F cooperates with the ‘p53-repressed miR cluster’i n
regulating shared targets at the transcriptional and post-
transcriptional levels. This suggests that the FFL consisting of
E2F and miRs-106b/93/25 may be deregulated during cancer
progression. We note that a ﬁfth of the predicted targets of the
miR cluster show a very different expression pattern
(Figure 6C, bottom part), which may indicate more complex
regulatory interactions.
Havingshownthemoleculareffectsof theoverexpressionof
the miR-106b/93/25 polycistron, we tested whether prolifera-
tion-related parameters such as growth rate, colony formation
efﬁciency (CFE) and replicative senescence are affected by
these miRs. As these miRs are signiﬁcantly repressed by p53
during senescence, and considering the fact that they target
several antiproliferation regulators, we predicted that their
overexpression,similarlytop53inactivation,wouldaccelerate
cellular growth rate and delay senescence. Indeed, as depicted
in Figure 7, the miR-106b/93/25-overexpressing WI-38 cells
demonstrated amoderateaccelerationinproliferation rateand
anincreasedfractionofS-phasecells(24%comparedto18%).
Strikingly, these cells displayed a pronounced increase in the
efﬁciency of young cells to form colonies when seeded at low
density and reduced senescence-associated beta-galactosidase
(SA-b-Gal) staining at late passages, indicating a delay of
replicative senescence. Additionally, we evaluated the effect of
miR-106b/93/25 overexpression in WI-38 cells on their CFE in
combination with p53 inactivation. As depicted in Supple-
mentary Figure S5, miR-106b/93/25 enhanced the CFE of both
active and inactive p53-expressing cells.However, the effect of
the overexpressed miRs was much more pronounced in the
active p53 cells, augmenting their CFE by 20-fold as compared
with only 2.6-fold increase in CFE in the inactive p53 cells. In
fact, the effect of overexpression of the miRs on the CFE of the
control cells was comparable to that of p53 inactivation. These
observed phenotypes suggest that the transcriptional repres-
sionofmiR-106b/93/25andtheir paralogsmediates partofthe
antiproliferative effects of p53.
Discussion
In the present study, we elucidate a complex regulatory
network involving a group of cancer-related miRs. In this
network, E2F1 transcriptionally controls the miR-106b/93/25
polycistron and its paralogs, and together they regulate a
mutual set of target genes. In concordance with the growth
acceleration that resulted from the overexpression of these
miRs, many of their targets are considered antiproliferative
cell-cycle regulators. Importantly, this intricate FFL is re-
pressed by p53 through inhibition of E2F1. A schematic model
for the proposed network is presented in Figure 8.
Employing three independent experiments, we identiﬁed a
novel miR signature that is transcriptionally repressed by p53
in human primary cells and in breast cancers. Consistent with
p53 function, many signature members, including the three
paralogous polycistrons and miR-155, are considered onco-
genic miRs and are overexpressed in diverse types of tumors
(Eis et al, 2005; He et al, 2005; Volinia et al, 2006; Yanaihara
et al, 2006). miR-15b and miR-16, which are considered to be
tumor suppressor miRs (Cimmino et al, 2005), are exceptions
in this regard.
Upon diverse stress stimuli, p53 is known to regulate
different subsets of genes, resulting in alternative cellular
outcomes (Oren, 2003). Consistently, the repression of the
miRs was restricted to non-genotoxic contexts, namely,
replicative senescence and Nutlin-induced Mdm2 inhibition,
as doxorubicin treatment did not result in transcriptional
repressionofthemiRclusterdespitep53activation.Ourearlier
studies have shown that Nutlin treatment induces p53-
dependent senescence accompanied by upregulation of
miR-34 (Kumamoto et al, 2008). Therefore, the repression of
the miRs might be speciﬁc to p53-induced senescence
triggered in this study by cellular aging or Nutlin treatment.
As p53 is capable of inducing senescence in vivo (Xue et al,
2007), the observed miRNA repression in the wild-type
p53-harboringbreasttumorsmaybeassociatedwithincreased
senescence in these samples.
Co-clustering of coding mRNAs and microRNAs from the
breast cancer study separated the p53-repressed miRs into two
p53-repressed miRNAs promote proliferation
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‘immune response’ (Figure 3). The expression-based division
perfectly mirrored earlier reported functions of these miRs,
including members of the three paralogous polycistrons that
were co-clustered with cell-cycle-associated mRNAs, and were
shown here and in additional reports (Hossain et al, 2006; Lu
et al, 2007; Ivanovska et al, 2008)to promote cell proliferation.
Anotherp53-repressedpolycistron,miR-15b/16,wasclustered
with the cell-cycle genes. Indeed, members of this polycistron
havebeenimplicatedintheregulationofcell-cycleprogression
(Linsley et al, 2007). The ‘immune response-associated
co-cluster’ included miR-155, which is commonly overex-
pressed in lymphomas (Eis et al, 2005), participates in the
germinal center response (Thai et al, 2007), and is upregulated
in chronic gastritis (Petrocca et al, 2008). The remaining
members of this co-cluster were also implicated in immune
responses,including miR-150 and miR-146 (Lodish et al, 2008)
as well as miR-142 (Wu et al, 2007). Overexpression of miR-
155 in primary cells did not affect the rate of proliferation
(Supplementary Figure S3F), suggesting distinct functions for
the members of the ‘immune response-associated co-cluster.’
Interestingly, in addition to many cell-cycle-related coding
genes reported to be repressed by p53, recent evidence
indicates p53-mediated repression of immune response-
related genes (e.g. interleukin-1b, interleukin-6 and Cxcl1
(Buganimetal,submitted)andSDF-1(Moskovitsetal,2006)).
For the ﬁrst time, we demonstrate that the three paralogous
polycistronic miRNAs are coordinately activated by E2F1.
Importantly, we establish E2F1 as the mediator of the p53-
dependent repression of miRs-106b/93/25 and suggest that
this mechanism underlies the repression of the two additional
paralogous polycistrons. Upon Nutlin treatment, E2F1 protein
levels were dramatically downregulated in a p53-dependent
manner.Asimilarphenomenonwasdescribedearlier,andwas
attributed to enhanced ubiquitylation of E2F1 by an unknown
ligase, resulting in proteasome-mediated degradation (Am-
brosini et al, 2007). However, we demonstrate that Nutlin
treatment also results in a robust p53-dependent E2F1 mRNA
repression, in agreement with an earlier observation that
overexpression of p53, as well as p21, results in down-
regulation of E2F1 mRNA (Ookawa et al, 2001). It is plausible
that p53-mediated reduction in E2F1 protein inhibits E2F1
transcriptionasthis genecontains anE2F motif inits promoter
and is itself an E2F target gene (Johnson et al, 1994). Thus,
even a slight reduction in E2F1 protein level might trigger a
feedback loop that will result in signiﬁcant reduction of both
protein and mRNA levels. Considering this feedback loop,
inhibition of E2F1 activity could also explain the observed
repression of its mRNA and protein levels. Such inactivation
may be indirectly mediated by the p53 target gene p21 through
the inhibition of CDKs that inactivate the pocket proteins,
which in turn inhibit E2F activity. Another mechanism for
Figure 7 Overexpression of miR-106b/93/25 polycistron in WI-38 cells promotes proliferation. Overexpression of miR-106b/93/25 polycistron in WI-38 cells promotes
proliferation. (A) Growth curves for control (empty vector) and miR-106b/93/25-overexpressing cells. PDLs, population doublings. The difference between the growth
curves was analyzed by paired t-test of the number of PDLs in each passage, and was found to be statistically signiﬁcant (P-value¼1.2 10
 4)( B) Cell-cycle analysis
of BrDU-labeled cells using ﬂuorescence cytometer. miR-106b/93/25-expressing cells demonstrated increased proportion of S phase (BrDU positive) cells. (C) Colony
formationassay.Cellswereplatedatlowdensityandgrownfor2weeks.Plateswerestainedwithcrystalviolet(left).Thecrystalvioletwasextracted withaceticacidand
quantiﬁed with a spectrophotometer using a 590nm ﬁlter (right). The difference was statistically signiﬁcant (P-valueo0.05). (D) Senescence-associated
b-galactosidase staining depicting decreased level of senescence in miR-106b/93/25-expressing cells as compared with their empty vector control counterparts (Con).
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BTG3 as a p53 target gene that directly binds E2F1 and inhibits
its activity (Ou et al, 2007). Yet another possible mediator for
p53-dependent E2F1 suppression is miR-34a, a direct tran-
scriptional target of p53, which was recently suggested to
induce senescence and to repress the E2F pathway (Tazawa
et al, 2007).
Earlier studies have reported the effect of a single miR on a
single target gene, such as miR-106b effect on p21 (Ivanovska
et al, 2008). Others have described E2F-dependent activation
ofasinglepolycistron,miR-17-92(Sylvestreetal, 2007; Woods
et al, 2007), and miRs-106b/93/25 (Petrocca et al, 2008). We
suggest that the three polycistrons, consisting of a family of 15
different miRs, are in fact transcriptionally co-regulated
directly by E2F and indirectly by p53. In addition, many miRs
in this family share highly similar seed sequences (Tanzer and
Stadler, 2004). Thus, when an entire miR family is coordi-
nately activated, its combinatorial and cumulative effects on
mRNA targets may be profound. To recapitulate natural
conditions, we combinatorially expressed three of the family
miRs (miRs-106b/93/25), which are naturally co-transcribed,
anddemonstratedtheireffectonasetoftargetproteins.Future
technologies allowing combinatorial knock down of an entire
miR family may further establish their effects on other target
genes.We showthat miRs-106b/93/25 silence key membersof
theE2F pathway, including negative regulatorsof proliferation
such as the pocket proteins pRb and p130 and the CDK
inhibitors p21 and p57 (Figure 6). These and many other cell-
cycle regulators are known E2F targets and are predicted to be
silencedbymiRs-106b/93/25(SupplementaryTableS5).Thus,
we provide experimental evidence for our recent in silico
predicted FFL motif (Shalgi et al, 2007).
We demonstrate here (Figure 6) a cancer-related manifesta-
tion of the concept of miR target avoidance (Farh et al, 2005;
Stark et al, 2005). These studies introduced the concept of
‘spatio-temporal avoidance,’ showing that miRs and their
targets tend to avoid being expressed in the same tissue or at
the same developmental time, thereby assisting to determine
differentiation boundaries and transitions. This avoidance
couldreﬂectadirectnegativeregulatoryeffectofthemiRonits
target. Alternatively, miR target avoidance may be mediated
through a common transcriptional program controlling both
the miRs and their targets.
The overexpression of miRs-106b/93/25 phenotypically
mimicked p53 inactivation in WI-38 cells, as evident from an
elevated rate of proliferation, increased CFE and delay of
senescence. Importantly, induction of senescence, which we
suggest to be partially mediated by the repression of the
polycistronic miRs described above, is considered one of the
main mechanisms by which p53 suppresses tumor formation
(Xue et al, 2007).
In summary, we present here another arm of p53’s tight
control of cell proliferation, senescence and tumor suppres-
sion. This involves an elaborate network encompassing miRs
and their targets, which modulate cell fate both during normal
growth and in cellular senescence.
Materials and methods
Cell culture
WI-38, MRC5, IMR90 (obtained from theATCC) and PFCA179 (provided
by Dr H Klocker) cells were cultured in MEM with 10% FCS (fetal calf
serum), 1mM sodium pyruvate, 2mM L-glutamine and antibiotics.
U2OS and H1299 cell lines were cultured in DMEM and RPMI,
respectively, with 10% FCS and antibiotics. MCF10A cells were
maintained in DMEM F12 supplemented with 5% horse serum, 0.5mg/ml
hydrocortisone, 0.1mg/ml insulin, 0.1mg/ml cholera toxin and
10ng/ml EGF. All cells were maintained in a humidiﬁed incubator at
371C and 5% CO2. Primary ﬁbroblasts were passaged every 5–6 days.
PDLs were calculated using the formula: PDLs¼log(cell output/cell
input)/log2. For colony formation assays, cells were plated at low
density (0.1–0.2 cells/mm
2), grown for 10–14 days and stained with
crystal violet.
Plasmids and retroviral infections
The retrovirus encoding for GSE56 was described by Milyavsky et al
(2005). shRNAs targeting p53 (p53i), or mouse NOXA (control shRNA)
were stably expressed using pRetroSuper and were described by
Berkovich and Ginsberg (2003). pRetroSuper-E2F1 was described by
Korotayev et al (2008). ER-E2F1 was described by Vigo et al (1999). E1A
was expressed from pBabe-puro-E1A12S (a gift from K Helin). For
expression of miRs-106b/93/25, a 1-kb human genomic fragment was
cloned with the primers 50-ggatcctatcctgcgcctttcc-30 and 50-cacatggcca-
cagaagac-30 into miR-Vec (Voorhoeve etal, 2006). For expression of miR-
155, a 238-bp human genomic fragment was cloned with the primers
50-gtggcacaaaccaggaag-30 and 50-tatccagcagggtgactc-30 into miR-Vec.
RetrovirusinfectionproceduresweredescribedbyMilyavskyetal(2003).
RNA preparation and quantitative real-time PCR
RNAwas extracted with TRI reagent (Molecular Research Center Inc.).
For mRNA quantiﬁcation, a 2mg aliquot of total RNA was reverse
transcribed using Bio-RT (Biolab) and random hexamers. Quantitative
Figure 8 A schematic model for the cell-cycle regulatory network comprising
E2F, p53, miRs and other cell-cycle regulators. Arrows correspond to direct
transcriptional activation, whereas bar-headed lines represent direct or indirect
inhibition mediated by the following mechanisms: post-transcription gene
silencing (miRNAs and their targets), protein binding and inactivation (pocket
proteinsand E2Fs;as wellasCDK inhibitors andCDKs,that inturninhibit pocket
proteins by phosphorylation). The circular arrow represents E2F self-activating
ability. Possible mechanisms underlying the repression of E2F by p53 are
detailed in the discussion.
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qPCR SuperMix (Invitrogen). mRNA levels were normalized to the
level of GAPDH in the same sample. Primer sequences are listed in
Supplementary Table S6A. For miRNAquantiﬁcation, TaqMan miRNA
assays (Applied Biosystems) were used according to the manufac-
turer’s protocol. Levels were normalized to the U6 control gene. All
QRT–PCR reactions were performed on ABI7300 machine. Results are
presented as mean and standard deviation for two or three duplicate
runs.
miRNA microarrays, data analysis and clustering
ThemiRNAproﬁlingpresentedinFigure1Awasperformedasfollows:
RNA was extracted from WI-38 cells using TRI reagent as described
above, labeled with Hy5 and hybridized on Exiqon’s miRCURYt LNA
Array (v.8.1) with a common reference Hy3-labeled RNA pool. Data
are provided as Supplementary dataset S1. Two biological replicates
were performed for each sample type. Hy5/Hy3 ratios were log2
transformed and ﬁltered such that miRs that were undetected in 11 or
12 samples were discarded. Duplicates were averaged, such that each
miR was represented by six values, corresponding to the six different
samples.Foreach miR, a credibilityvaluewascalculatedas one minus
the average of the six standard deviations (s.d.) between the
duplicates. A duplicate that had one missing value was set as the
detected value and was assigned with high s.d. The 5% most non-
credible miRs were discarded. Data were clustered using hierarchical
clustering (average linkage), with 20 clusters. The miRNA proﬁling
presented in Figure 1B was performed as follows: RNA was extracted
from young and old WI-38 and MRC5 cells using TRIZOL (Invitrogen)
according to the manufacturer’s protocol and was used for biotin
labeling and hybridization on the version 4.0 miR arrays (Ohio State
University) as describedby Liu et al (2004). Datawere normalized and
log2-transformed. Data are provided as Supplementary dataset S2.
Data were clustered using hierarchical clustering (average linkage),
with 10 clusters. The miRNA proﬁling presented in Figure 1C was
performed as follows: RNA was extracted as described by Sorlie et al
(2006). Samples were hybridized on Agilent’s miRNA arrays (beta
version of V1) at the Agilent’s facilities in St Clara, US by HJ. Data are
provided as Supplementary dataset S3. Two outlier samples (both
belonging to the mutant p53 set) were discarded (see Supplementary
Figure S6). Data were clustered using hierarchical clustering (average
linkage), with 25 clusters.
Microarraydatacan bedownloaded from the GEO database (http://
www.ncbi.nlm.nih.gov/geo/). Accession numbers are as follows:
GSE12450 (the WI-38 p53-dependent senescence study), GSE12821
(the WI-38 and MRC5 senescence study) and GSE12848 (The Breast
Cancer Study).
Co-clustering of miRNA and mRNA expression
data from human breast cancer samples
mRNA array data were ﬁltered and normalized as in Sorlie et al (2006)
(GEO accession number GSE3155) and only samples that were
included in the miRNA analysis were used. Data were log2-
transformed,andreplicatemRNAprobeswereaveraged.Onlyvariable
mRNAs that differ by at least 1.5-fold from their median expression in
at least 40% of the samples were considered. miRNA data were
centered such that the intensity values for each miR were divided by
their mean, and log2 transformed. The combined mRNA and miRNA
data were then clustered using hierarchical clustering (average
linkage) with 40 clusters. miRs from the ‘breast cancer p53-repressed
miR cluster’ were mapped to the resulting co-clusters, and were found
to reside in two clusters, that were then analyzed for functional
enrichment using DAVID (Dennis et al, 2003), and for enrichment of
sequencemotifsintheircorrespondingENSMBLgenepromotersusing
AMADEUS (Linhart et al, 2008).
Analysis of miRNA targets expression coherence
The entire set of miRNA expression proﬁles was clustered into 20 miR
clusters based on the above expression data (WI-38 young versus
senescent, along with p53 inactivation). Then, we compiled a set of
predicted targets for the miRs from each cluster using PicTar (Krek
et al, 2005). Speciﬁcally, for each of the 20 miR clusters, a series of
potential sets of targets were created. The ﬁrst set consisted of mRNAs
predicted to be targeted by at least one miR from the miR cluster. The
second set consisted of mRNAs predicted to be targeted by at least two
miRs from the miR cluster, and so on. The expression coherence (EC)
score, a measure of expression similarity (Pilpel et al, 2001), was then
computed for each set of targets according to their expression
described byMilyavsky et al (2005) (expression data are also available
as Supplementary dataset S5). The most signiﬁcantly coherent
expression pattern belonged to the set of genes that had target sites
for at least ﬁve miRs from the ‘p53-repressed miR cluster’ (EC
P-value¼5 10
 3). The expression values for this gene set in the data
from Milyavsky et al (2005) and prediction of E2F sites are found in
Supplementary Figure S4.
Immunoblot analysis
Western blots were performed as described by Milyavsky et al (2005).
The following antibodies were used: a-p53 pAb H-47 (produced in our
laboratory), a-p21 sc-377 (Santa Cruz), a-E2F1 sc-193 (Santa Cruz),
a-GAPDH MAB374 (Chemicon), a-p130 sc-317 (Santa Cruz), a-p57
sc-8298 (Santa Cruz), a-pRb 554136 (Pharmingen), and a–b-tubulin
T7816 (Sigma).
Cell-cycle analysis
Cellswerelabeledfor30minwith10mMBrdU(Sigma),ﬁxedwith70%
EtOH/HBSS (2h,  201C), treated with 2M HCl/0.5% Triton, washed
and treated with 0.1M Na2B4O7 pH 8.5, and stained with FITC-
conjugated anti-BrdU (Becton Dickinson) and 10mg/ml propidium
iodide. Samples were analyzed using a FACSort machine (Becton
Dickinson). At least 1 10
4 events were recorded per sample.
SA-b-Gal activity assay
Cells were ﬁxed with 3% formaldehyde/PBS for 5min, washed with
PBS and incubated for 16h at 371C with a solution containing 1mg/ml
X-gal, 40mM citric acid, sodium phosphate, pH 6.0, 5mM potassium
ferrocyanide, 5mM potassium ferricyanide, 150mM NaCl and 2mM
MgCl2.
Chromatin immunoprecipitation
DNA–protein complexes were immunoprecipitated from U2OS cells
using the ChIP assay kit (Upstate Biotechnology), according to the
manufacturer’s protocol with the following polyclonal antibodies:
a-E2F1 sc-193 (Santa Cruz) and a-HA sc-805 (Santa Cruz); the latter
servedasacontrolfornonspeciﬁcDNAbinding.TheprecipitatedDNA
wassubjectedtoQRT–PCRanalysisusingspeciﬁcprimerscorrespond-
ing to each predicted E2F site, as well as primers for normalization
(b-tubulin) and negative control for E2F1 binding (b-actin coding
region). Primer sequences are listed in Supplementary Table S6B.
Supplementary information
Supplementary information is available at the Molecular Systems
Biology website (www.nature.com/msb).
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